2018-02-27
Aptahem AB (publ) is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved in the disease process. Aptahem is today pleased to announce the appointment...
Read More
2018-02-20
Aptahem AB (Aktietorget: APTA) a biotechnology company which is developing aptamer-based drugs for the treatment of life-threatening conditions in which coagulation and inflammation work together in the disease process, announces that production process of the company´s drug candidate Apta-1...
Read More
2018-01-17
Aptahem is today pleased to announce the recruitment to the company´s scientific advisory board of Hans Peter Schwarz and Mats Eriksson; two highly experienced and internationally recognised experts. Professor Hans Peter Schwarz, MD has previously held leading positions within...
Read More
2017-12-20
Aptahem is now able to announce that the development of a completely new bioanalysis method has been finalized in collaboration with our partner Axolab in Germany. The new method has a better resolution and can detect lower levels of...
Read More
2017-11-10
”Aptahem’s drug candidate shows sensationally good results in sepsis studies” The scientific advisory board has now been in place for almost a year, and we have interviewed the president of the board, Dr. Anders Bylock, about what has happened...
Read More
2017-10-03
Aptahem (publ) announced today that the company has submitted a new patent application based on the latest research results of Apta-1, with the aim of strengthening the company’s intellectual property rights portfolio. The new patent application is based on...
Read More
2017-09-12
Aptahem (publ) can announce today new positive results from an extended study performed with Hooke Laboratories (US), the collaborating partner. The results show that intravenous administration of Apta-1 correlates with an improved survival rate in test animals. The outcome...
Read More
2017-08-11
Aptahem AB (publ) can announce today that the company’s board has finalized a revised development plan for the drug candidate Apta-1. The new development plan was established together with the company’s scientific advisory board who assessed Apta-1’s pharmacological properties....
Read More
2017-08-10
Aptahem AB (publ) can announce today that it has entered into a production agreement with BioSpring, a world-leading producer of oligonucleotides. BioSpring has been contracted to manufacture the substance in drug candidate Apta-1 for the company’s preclinical and upcoming...
Read More
2017-07-28
Aptahem (publ) can today announce a positive outcome from a study performed in collaboration with Hooke Laboratories (US). The study evaluated the pharmaceutical candidate Apta-1 in a clinically relevant model for sepsis which showed a significant improvement in survival...
Read More